Trial Profile
A multicentric, retrospective study assessing safety and efficacy of Eribulin mesylate in elderly and younger patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EVHALAVEN
- 18 Jan 2016 New trial record